FY2025 EPS Estimates for BMRN Boosted by Cantor Fitzgerald

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) – Equities researchers at Cantor Fitzgerald lifted their FY2025 EPS estimates for BioMarin Pharmaceutical in a note issued to investors on Friday, May 2nd. Cantor Fitzgerald analyst O. Brayer now forecasts that the biotechnology company will post earnings per share of $3.61 for the year, up from their previous estimate of $3.53. Cantor Fitzgerald has a “Overweight” rating and a $90.00 price target on the stock. The consensus estimate for BioMarin Pharmaceutical’s current full-year earnings is $3.15 per share.

A number of other brokerages have also recently issued reports on BMRN. Oppenheimer raised BioMarin Pharmaceutical from a “market perform” rating to an “outperform” rating and set a $98.00 target price for the company in a research report on Monday, February 24th. Wedbush reiterated an “outperform” rating and issued a $94.00 target price on shares of BioMarin Pharmaceutical in a research note on Thursday, February 20th. Bank of America boosted their target price on shares of BioMarin Pharmaceutical from $99.00 to $103.00 and gave the stock a “buy” rating in a research report on Thursday, February 20th. Citigroup lowered their price target on BioMarin Pharmaceutical from $82.00 to $78.00 and set a “neutral” rating on the stock in a research report on Friday. Finally, Royal Bank of Canada reissued a “sector perform” rating and set a $70.00 price objective on shares of BioMarin Pharmaceutical in a research report on Thursday, February 20th. Seven research analysts have rated the stock with a hold rating, sixteen have assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $92.95.

BioMarin Pharmaceutical Stock Performance

BMRN opened at $62.03 on Monday. The company has a debt-to-equity ratio of 0.11, a quick ratio of 2.62 and a current ratio of 5.33. The company has a market cap of $11.84 billion, a PE ratio of 28.20, a price-to-earnings-growth ratio of 0.61 and a beta of 0.27. The stock has a 50-day moving average of $65.84 and a 200-day moving average of $65.71. BioMarin Pharmaceutical has a 52-week low of $52.93 and a 52-week high of $94.85.

BioMarin Pharmaceutical (NASDAQ:BMRN) last released its quarterly earnings data on Wednesday, February 19th. The biotechnology company reported $0.72 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.54 by $0.18. The business had revenue of $747.31 million during the quarter, compared to analyst estimates of $711.05 million. BioMarin Pharmaceutical had a net margin of 14.96% and a return on equity of 9.91%.

Insider Buying and Selling

In other BioMarin Pharmaceutical news, CAO Erin Burkhart sold 1,295 shares of the company’s stock in a transaction dated Wednesday, March 19th. The shares were sold at an average price of $71.52, for a total transaction of $92,618.40. Following the sale, the chief accounting officer now directly owns 16,955 shares of the company’s stock, valued at approximately $1,212,621.60. This represents a 7.10 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. 0.85% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On BioMarin Pharmaceutical

A number of large investors have recently bought and sold shares of the business. Farther Finance Advisors LLC grew its stake in shares of BioMarin Pharmaceutical by 95.9% during the first quarter. Farther Finance Advisors LLC now owns 431 shares of the biotechnology company’s stock valued at $29,000 after purchasing an additional 211 shares during the last quarter. LRI Investments LLC lifted its holdings in BioMarin Pharmaceutical by 856.9% during the 4th quarter. LRI Investments LLC now owns 488 shares of the biotechnology company’s stock worth $32,000 after buying an additional 437 shares in the last quarter. SBI Securities Co. Ltd. acquired a new position in BioMarin Pharmaceutical during the 4th quarter worth $36,000. MassMutual Private Wealth & Trust FSB boosted its position in BioMarin Pharmaceutical by 71.2% in the 1st quarter. MassMutual Private Wealth & Trust FSB now owns 524 shares of the biotechnology company’s stock valued at $37,000 after buying an additional 218 shares during the last quarter. Finally, CIBC Private Wealth Group LLC increased its stake in shares of BioMarin Pharmaceutical by 64.2% in the 4th quarter. CIBC Private Wealth Group LLC now owns 596 shares of the biotechnology company’s stock valued at $41,000 after buying an additional 233 shares during the period. 98.71% of the stock is currently owned by institutional investors.

About BioMarin Pharmaceutical

BioMarin Pharmaceutical Inc develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease.